Off-topic for aiqbench

This story was gathered from a source we follow but falls outside AI and quantum coverage, so there is no aiqbench take for it.

Montana’s plan to become an experimental medical hub just pushed forward

MIT Technology ReviewJuly 30, 20261 min read

As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to apply to a newly established review board for approval. Once its treatment is rubber-stamped, the…

Read the full article at MIT Technology Review

Read at MIT Technology Review ↗Ask about this article